Fat Brands Inc. shares rise 3.03% after-hours following positive Phase 2b QUALITY study results.

Fat Brands Inc. rose 3.03% in after-hours trading, with the company reporting positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone. The company also reported positive efficacy and safety data from Phase 2b QUALITY Maintenance Extension study showing enobosarm significantly reduced body weight regain, prevented fat regain, and preserved lean mass after semaglutide discontinuation. Additionally, the company has selected a novel modified release oral enobosarm formulation following pharmacokinetic clinical study and anticipates FDA feedback to clarify the regulatory pathway for enobosarm to preserve lean mass during chronic weight loss management.